axogen logo.jpg
Axogen, Inc to Participate at Leerink Partners Healthcare Crossroads Conference
14. Mai 2024 07:00 ET | Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., May 14, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...
axogen logo.jpg
Axogen, Inc Reports First Quarter 2024 Financial Results
02. Mai 2024 07:00 ET | Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., May 02, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...
axogen logo.jpg
Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™
29. April 2024 16:50 ET | Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., April 29, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve...
axogen logo.jpg
Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
16. April 2024 07:00 ET | Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve...
axogen logo.jpg
Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap
18. Januar 2024 17:00 ET | Axogen, Inc.
REPOSE® met its primary endpoint of non-inferiority between the pain visual analog scale outcomes for neurectomy with Axoguard Nerve Cap® vs. standard-of-care neurectomy at Month 12. Axoguard Nerve...
axogen logo.jpg
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023
04. Januar 2024 16:45 ET | Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...
axogen logo.jpg
Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025
04. Januar 2024 16:40 ET | Axogen, Inc.
ALACHUA and TAMPA, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today...
axogen logo.jpg
Axogen Announces Promotions on Research and Development Team
04. Januar 2024 16:35 ET | Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) --  Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve...
axogen logo.jpg
Axogen, Inc. Appoints Kathy Weiler to its Board of Directors
26. Dezember 2023 16:15 ET | Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...
axogen logo.jpg
Axogen Announces Transition of Finance Team Leadership
06. Dezember 2023 07:00 ET | Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...